Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by (12,156)

Items 501–600 of 12,156

1. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
   Christopher Paul Cannon, Darren K. McGuire, Richard E. Pratley, Samuel E. Dagogo-Jack, James P. Mancuso, Susan B. Huyck, Bernard H. Charbonnel, Weichung Shih, Silvina Gallo, URSZULA S. MASIUKIEWICZ et al. · 2018 · American Heart Journal
2. Effects of dapagliflozin in stage 4 chronic kidney disease
   Chertow, Glenn M., Vart, Priya, Jongs, Niels, Toto, Robert D., Gorriz, Jose Luis, Hou, Fan Fan, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David et al. · 2021 · Journal of the American Society of Nephrology
3. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)
   Patrick B. Ryan, John B. Buse, Martijn J. Schuemie, Frank DeFalco, Žhong Yuan, Paul Stang, Jesse A. Berlin, Norman R Rosenthal · 2018 · Diabetes Obesity and Metabolism
4. Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
   Stefan D. Anker, Muhammad Usman, Markus S. Anker, Javed Butler, Michael Böhm, William T. Abraham, Marianna Adamo, Vijay Chopra, Mariantonietta Cicoira, Francesco Cosentino et al. · 2023 · European Journal of Heart Failure
5. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
   Michaël J.B. van Baar, Charlotte C. van Ruiten, Marcel H.A. Muskiet, Liselotte van Bloemendaal, Richard G. IJzerman, Daniël H. van Raalte · 2018 · Diabetes Care
6. The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review
   Garrison J. B. Dyck, Pema Raj, Shelley R. Zieroth, Jason R.B. Dyck, Justin Adrian Ezekowitz · 2019 · International Journal of Molecular Sciences
7. Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
   Amelia Charlton, Jessica Garzarella, Karin Agnes Maria Jandeleit-Dahm, Jay C. Jha · 2020 · Biology
8. 13. Older Adults: Standards of Care in Diabetes—2023
   Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Marisa E. Hilliard, Diana M. Isaacs, Eric L. Johnson et al. · 2022 · Diabetes Care
9. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition
   Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova, Alexander Yur'evich Mayorov, Ol'ga Konstantinovna Vikulova, Gagik Radikovich Galstyan, Тамара Леонидовна Кураева, Valentina Aleksandrovna Peterkova, Olga Mikhailovna Smirnova, Elena Georgievna Starostina, Elena Viktorovna Surkova et al. · 2017 · Diabetes Mellitus
10. Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
    Azoulay, Laurent, Suissa, Samy · 2017 · Diabetes Care
11. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis
    Jan Menne, Eva Dumann, Hermann G. Haller, Bernhard M. W. Schmidt · 2019 · PLoS Medicine
12. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis
    Siddharth M. Patel, Yu Mi Kang, KyungAh Im, Brendon Lange Neuen, Stefan D. Anker, Deepak L. Bhatt, Javed Butler, David Z.I. Cherney, Brian Lee Claggett, Robert A. Fletcher et al. · 2024 · Circulation
13. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
    Dufour, Jean-François, Caussy, Cyrielle, Loomba, Rohit · 2020 · Gut
14. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3a): the DERIVE Study
    Fioretto, Paola, Del Prato, Stefano, Buse, John B., Goldenberg, Ronald, Giorgino, Francesco, Reyner, Daniel, Langkilde, Anna Maria, Sjöström, C. David, Sartipy, Peter, On Behalf of the DERIVE Study Investigators · 2018 · Diabetes, Obesity and Metabolism
15. Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets
    Nikoletta Pechlivani, Ramzi Ajjan · 2018 · Frontiers in Cardiovascular Medicine
16. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency
    Kim L. Ho, Liyan Zhang, Cory S. Wagg, Rami Al Batran, Keshav Gopal, Jody L. Levasseur, Teresa C. Leone, Jason R.B. Dyck, John R. Ussher, Deborah M. Muoio et al. · 2019 · Cardiovascular Research
17. Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials
    Basu, Sanjay, Sussman, Jeremy B, Berkowitz, Seth A, Hayward, Rodney A, Yudkin, John S · 2017 · The Lancet Diabetes & Endocrinology
18. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
    Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito, Tsutomu Hirano · 2017 · Cardiovascular Diabetology
19. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association
    Rangaswami, Janani, Bhalla, Vivek, de Boer, Ian H., Staruschenko, Alexander, Sharp, Johanna A., Singh, Radhika Rajgopal, Lo, Kevin Bryan, Tuttle, Katherine, Vaduganathan, Muthiah, Ventura, Hector et al. · 2020 · Circulation
20. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus
    Panai Song, Akira Ōnishi, Hermann Koepsell, Volker Vallon · 2016 · Expert Opinion on Therapeutic Targets
21. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
    Sven Köhler, Cordula Zeller, Hristo Iliev, Stefan Kaspers · 2017 · Advances in Therapy
22. Heart failure in patients with kidney disease
    Courtney Tuegel, Nisha Bansal · 2017 · Heart
23. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
    Mark Sweeney, Ben Corden, Stuart A. Cook · 2020 · EMBO Molecular Medicine
24. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
    Sano, Motoaki · 2018 · Journal of Cardiology
25. Lower extremity arterial disease in patients with diabetes: a contemporary narrative review
    Mathilde Nativel, Louis Potier, Laure Alexandre, Laurence Baillet‐Blanco, Eric Ducasse, Gilberto Velho, Michel Marre, Ronan Roussel, Vincent Rigalleau, Kamel Mohammedi · 2018 · Cardiovascular Diabetology
26. Hypertrophic Cardiomyopathy: The Future of Treatment
    C. Vaughan Tuohy, Sanjiv Kaul, Howard K. Song, Babak Nazer, Stephen B. Heitner · 2020 · European Journal of Heart Failure
27. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
    Chintan N. Koyani, Ioanna Plastira, Harald Sourij, Seth Hallström, Albrecht G. Schmidt, Peter P. Rainer, Heiko Bugger, Saša Frank, Ernst Malle, Dirk von Lewinski · 2020 · Pharmacological Research
28. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
    David Collins. Wheeler, Bergur V. Stefánsson, М. М. Батюшин, Oleksandr V. Bilchenko, David Z.I. Cherney, Glenn Matthew Chertow, Walter Douthat, Jamie P. Dwyer, Elizabeth Escudero, Roberto Pecoits‐Filho et al. · 2020 · Nephrology Dialysis Transplantation
29. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
    Takeshi Kitai, Shun Kohsaka, Takao Kato, Eri Toda Kato, Kimi Sato, KANAKO TERAMOTO, Hidenori Yaku, Eiichi Akiyama, Masahiko Ando, Chisato Izumi et al. · 2025 · Circulation Journal
30. Combination therapy with <scp>GLP</scp> ‐1 receptor agonist and <scp>SGLT2</scp> inhibitor
    DeFronzo, Ralph A. · 2017 · Diabetes, Obesity and Metabolism
31. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms
    Lee, P. C., Ganguly, S., Goh, S.‐Y. · 2018 · Obesity Reviews
32. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
    Fumitaka Soga, Hidekazu Tanaka, Kazuhiro Tatsumi, Yasuhide Mochizuki, Hiroyuki Sano, Hiromi Toki, Kensuke Matsumoto, Junya Shite, Hideyuki Takaoka, Tomofumi Doi et al. · 2018 · Cardiovascular Diabetology
33. Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy
    Miriam Longo, Giuseppe Bellastella, Maria Ida Maiorino, Juris Jendrik Meier, Katherine Esposito, Dario Giugliano · 2019 · Frontiers in Endocrinology
34. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
    Devinder Singh Dhindsa, Pratik B. Sandesara, Michael David Shapiro, Nathan D. Wong · 2020 · Frontiers in Cardiovascular Medicine
35. Sex- and Gender-Based Pharmacological Response to Drugs
    Franck Mauvais‐Jarvis, Heiner K. Berthold, Ilaria Campesi, Juan Jesús Carrero, Santosh Dhakal, Flavia Franconi, Ioanna Gouni‐Berthold, Mark L. Heiman, Alexandra Kautzky‐Willer, Sabra L. Klein et al. · 2021 · Pharmacological Reviews
36. SGLT2 Inhibitors: Physiology and Pharmacology
    Ernest M. Wright · 2021 · Kidney360
37. Diabetic Nephropathy: a Tangled Web to Unweave
    Corey Magee, David Grieve, Chris J Watson, Derek P. Brazil · 2017 · Cardiovascular Drugs and Therapy
38. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications
    Claudio Tana, Stefano Ballestri, Fabrizio Ricci, Angelo Di Vincenzo, Andrea Ticinesi, Sabina Gallina, Maria Adele Giamberardino, Francesco Cipollone, Richard Sutton, Roberto Vettor et al. · 2019 · International Journal of Environmental Research and Public Health
39. Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies
    Carlo Alberto Ricciardi, Luigi Gnudi · 2021 · Metabolism
40. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
    Agata Winiarska, Monika Knysak, Katarzyna Nabrdalik, Janusz Gumprecht, Tomasz P. Stompór · 2021 · International Journal of Molecular Sciences
41. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus
    Lai, Lee-Lee, Vethakkan, Shireene Ratna, Nik Mustapha, Nik Raihan, Mahadeva, Sanjiv, Chan, Wah-Kheong · 2020 · Digestive Diseases and Sciences
42. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
    Beatrice C. Lupsa, Silvio E. Inzucchi · 2018 · Diabetologia
43. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
    Bo Xu, Shaoqian Li, Bo Kang, Jiecan Zhou · 2022 · Cardiovascular Diabetology
44. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy
    Yu Ho Lee, Sang Hoon Kim, Jun Mo Kang, Jin Hyung Heo, Dong-Jin Kim, Seon Hwa Park, Min Ji Sung, Jaehee Kim, Jisu Oh, Dong Ho Yang et al. · 2019 · American Journal of Physiology-Renal Physiology
45. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
    Nadkarni, Girish N., Ferrandino, Rocco, Chang, Alexander, Surapaneni, Aditya, Chauhan, Kinsuk, Poojary, Priti, Saha, Aparna, Ferket, Bart, Grams, Morgan E., Coca, Steven G. · 2017 · Diabetes Care
46. Diabetes Mellitus and Heart Failure
    Michael Lehrke, Nikolaus Marx · 2017 · The American Journal of Medicine
47. Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
    Laween Uthman, Antonius Baartscheer, Cees A. Schumacher, Jan W.T. Fiolet, Marius C. Kuschma, Markus Werner Hollmann, Ruben Coronel, Nina Claudia Weber, Coert Jozef Zuurbier · 2018 · Frontiers in Physiology
48. NLRP3 inflammasome as a key driver of vascular disease
    Masafumi Takahashi · 2021 · Cardiovascular Research
49. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
    Hang‐Long Li, Gregory Y.H. Lip, Qi Feng, Yue Fei, Yi-Kei Tse, Mei-zhen Wu, Qing-Wen Ren, Hung‐Fat Tse, Bernard M.Y. Cheung, Kai‐Hang Yiu · 2021 · Cardiovascular Diabetology
50. JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
    Hiroyuki Tsutsui, Tomomi Ide, Hiroshi Ito, Yasuki Kihara, Koichiro Kinugawa, Shintaro Kinugawa, Miyuki Makaya, Toyoaki Murohara, Koichi Node, Yoshihiko Saito et al. · 2021 · Circulation Journal
51. Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis
    Mehar Sahu, Rohan V. Gupta, Rashmi K. Ambasta, Pravir Kumar · 2022 · Progress in molecular biology and translational science
52. The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer
    Hermann Koepsell · 2016 · Pharmacology & Therapeutics
53. Pharmacotherapy of type 2 diabetes: An update
    Jagriti Upadhyay, Stergios A. Pοlyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula Α. Paschou, Niki Katsiki, PATRICIA C. UNDERWOOD, Kyung‐Hee Park, Jochen Seufert, Eun Seok Kang et al. · 2017 · Metabolism
54. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
    Kai Jiang, Yue Xu, Dandan Wang, Feng Chen, Zizhuo Tu, Jie Qian, Sheng Xu, Yixiang Xu, John Hwa, Jian Li et al. · 2021 · Protein & Cell
55. The Effects of SGLT2 Inhibitors on Lipid Metabolism
    Zsolt János Szekeres, Kálmán Tóth, Eszter Szabados · 2021 · Metabolites
56. Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development
    Holmes, Michael V., Richardson, Tom G., Ference, Brian A., Davies, Neil M., Davey Smith, George · 2021 · Nature Reviews Cardiology
57. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
    Khawaja Muhammad Talha, Stefan D. Anker, Javed Butler · 2023 · International Journal of Heart Failure
58. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial
    Buse, John B., Bain, Stephen C., Mann, Johannes F.E., Nauck, Michael A., Nissen, Steven E., Pocock, Stuart, Poulter, Neil R., Pratley, Richard E., Linder, Martin, Monk Fries, Tea et al. · 2020 · Diabetes Care
59. SGLT 2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature
    Kelly R. Burke, Christie Schumacher, Spencer E. Harpe · 2016 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
60. Heart Failure With Mid-Range (Borderline) Ejection Fraction
    Jeffrey J. Hsu, Boback Ziaeian, Gregg C. Fonarow · 2017 · JACC Heart Failure
61. Precision medicine in the management of type 2 diabetes
    Anna L. Gloyn, Daniel J. Drucker · 2018 · The Lancet Diabetes & Endocrinology
62. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
    Antonios Douros, Lisa Marie Lix, Michael Fralick, Sophie Dell’Aniello, Baiju R. Shah, Paul Everett Ronksley, Éric Tremblay, Nianping Hu, Silvia Alessi‐Severini, Anat Fisher et al. · 2020 · Annals of Internal Medicine
63. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection
    Marco Bruno Morelli, Chiara Bongiovanni, Silvia Da Pra, Carmen Miano, Francesca Sacchi, Mattia Lauriola, Gabriele D’Uva · 2022 · Frontiers in Cardiovascular Medicine
64. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
    H. Gerstein, H. Colhoun, G. Dagenais, R. Diaz, M. Lakshmanan, P. Pais, J. Probstfield, M. Riddle, L. Rydén, D. Xavier et al. · 2018 · Diabetes, obesity and metabolism
65. Uric acid and the cardio‐renal effects of SGLT2 inhibitors
    Clifford J. Bailey · 2019 · Diabetes Obesity and Metabolism
66. Diabetes Mellitus and Cardiovascular Disease
    Ann Marie Schmidt · 2019 · Arteriosclerosis Thrombosis and Vascular Biology
67. SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
    Carolyn S.P. Lam, Chanchal Chandramouli, Vineeta Ahooja, Subodh Verma · 2019 · Journal of the American Heart Association
68. The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
    Kerstin N. Timm, Damian J. Tyler · 2020 · Cardiovascular Drugs and Therapy
69. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis
    Cai, Xiaoling, Yang, Wenjia, Gao, Xueying, Chen, Yifei, Zhou, Lingli, Zhang, Simin, Han, Xueyao, Ji, Linong · 2018 · Obesity
70. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
    Marina V. Karg, Agnes Bosch, Dennis Kannenkeril, Kristina Striepe, C. Ott, Markus Peter Schneider, F. Boemke-Zelch, Peter R Linz, Armin Michael Nagel, Jens Marc Titze et al. · 2018 · Cardiovascular Diabetology
71. Renal Handling of Ketones in Response to Sodium–Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes
    Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Elisabetta Barsotti, Aldo Clerico, Elza Muscelli · 2017 · Diabetes Care
72. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
    Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca, Ofri Mosenzon, Eri Toda Kato, Avivit Cahn, Michael G. Silverman, Sameer Bansilal, Deepak L. Bhatt, Lawrence A. Leiter et al. · 2018 · American Heart Journal
73. Sodium–glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice
    Ting Cai, Qingqing Ke, Yi Fang, Ping Wen, Hanzhi Chen, Qi Yuan, Jing Luo, Yu Zhang, Qi Sun, Yunhui Lv et al. · 2020 · Cell Death and Disease
74. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury
    Charshawn Lahnwong, Siripong Palee, Nattayaporn Apaijai, Sirawit Sriwichaiin, Sasiwan Kerdphoo, Thidarat Jaiwongkam, Siriporn Chaisin Chattipakorn, Nipon Chattipakorn · 2020 · Cardiovascular Diabetology
75. Should metformin remain the first-line therapy for treatment of type 2 diabetes?
    Chelsea A. Baker, Cimmaron Retzik-Stahr, Vatsala Singh, Renee Plomondon, Victoria Anderson, Neda Rasouli · 2021 · Therapeutic Advances in Endocrinology and Metabolism
76. Japanese Clinical Practice Guideline for Diabetes 2016
    Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa, Hiroshi Noto, Daisuke Yabe, Yukihiro Fujita, Atsushi Goto, Tatsuya Kondo, Eiichi Araki · 2018 · Journal of Diabetes Investigation
77. 10. Microvascular Complications and Foot Care
    American Diabetes Association · 2016 · Diabetes Care
78. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
    Shusuke Yagi, Yukina Hirata, Takayuki Ise, Kenya Kusunose, Hirotsugu Yamada, Daiju Fukuda, Hotimah Masdan Salim, Gulinu Maimaituxun, Susumu Nishio, Yuriko Takagawa et al. · 2017 · Diabetology & Metabolic Syndrome
79. Diabetic Kidney Disease
    Ryan Bonner, Oltjon Albajrami, James C. Hudspeth, Ashish Upadhyay · 2020 · Primary Care Clinics in Office Practice
80. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
    Annayya Rao Aroor, Nitin A. Das, Andrea J. Carpenter, Javad Habibi, Guanghong Jia, Francisco I. Ramirez‐Perez, Luis Arturo Martinez‐Lemus, Camila Manrique‐Acevedo, Melvin Ray Hayden, Cornel Duta et al. · 2018 · Cardiovascular Diabetology
81. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
    Aysegul Toy Durak, Yusuf Olğar, Sinan Değirmenci, Erman Akkuş, Erkan Tuncay, Belma Turan · 2018 · Cardiovascular Diabetology
82. European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart Failure
    Petar M Seferovic, Andrew J.S. Coats, Piotr P. Ponikowski, Gerasimos S Filippatos, M Huelsmann, Pardeep S. Jhund, Marija M. Polovina, Michel Komajda N, Jelena P. Seferović, İbrahim Sarı et al. · 2019 · European Journal of Heart Failure
83. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
    Shruti Shree Joshi, Trisha Singh, David Ernest Newby, Jagdeep S. Singh · 2021 · Heart
84. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
    Maria Rosaria Rizzo, Irene Di Meo, Rita Polito, Maria Chiara Auriemma, Antonio Gambardella, Gabriella di Mauro, Annalisa Capuano, Giuseppe Paolisso · 2022 · Pharmacological Research
85. Diabetes mellitus and stroke: A clinical update
    Tun, Nyo Nyo, Arunagirinathan, Ganesan, Munshi, Sunil K, Pappachan, Joseph M · 2017 · World Journal of Diabetes
86. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
    Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini · 2020 · Diabetes Metabolic Syndrome and Obesity
87. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
    Christian Sonesson, Peter A. Johansson, EVA K. JOHNSSON, Ingrid A. M. Gause‐Nilsson · 2016 · Cardiovascular Diabetology
88. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
    Yoon‐Kyung Chang, Hyunsu Choi, Jin Young Jeong, Ki Ryang Na, Kang Wook Lee, Beom Jin Lim, Dae Eun Choi · 2016 · PLoS ONE
89. Medical Therapy for Heart Failure Caused by Ischemic Heart Disease
    Islam Y. Elgendy, Dhruv Mahtta, Carl J. Pepine · 2019 · Circulation Research
90. Preventing CKD in Developed Countries
    Valérie A. Luyckx, David Z.I. Cherney, Aminu K. Bello · 2019 · Kidney International Reports
91. Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
    Jiali Liu, Ling Li, Sheyu Li, Yuning Wang, Xuan Qin, Ke Deng, Yanmei Liu, Kang Zou, Xin Sun · 2020 · Diabetes Obesity and Metabolism
92. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( <scp>CANVAS‐R</scp> ): A randomized, placebo‐controlled trial
    Neal, Bruce, Perkovic, Vlado, Matthews, David R., Mahaffey, Kenneth W., Fulcher, Greg, Meininger, Gary, Erondu, Ngozi, Desai, Mehul, Shaw, Wayne, Vercruysse, Frank et al. · 2017 · Diabetes, Obesity and Metabolism
93. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
    Ryotaro Bouchi, Masahiro Terashima, Yuriko Sasahara, Masahiro Asakawa, Tatsuya Fukuda, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama et al. · 2017 · Cardiovascular Diabetology
94. Acute Kidney Injury and Progression of Diabetic Kidney Disease
    Samuel Mon-Wei Yu, Joseph Vincent Bonventre · 2018 · Advances in Chronic Kidney Disease
95. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
    CHIARA MARIA ASSUNTA CEFALO, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari · 2019 · Cardiovascular Diabetology
96. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets
    Jonatan Barrera‐Chimal, Frédéric Jaisser · 2020 · Diabetes Obesity and Metabolism
97. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy
    Nikole J. Byrne, Namakkal Soorappan Rajasekaran, E. Dale Abel, Heiko Bugger · 2021 · Free Radical Biology and Medicine
98. Impact of plant extracts upon human health: A review
    Mariana Veiga, Eduardo M. Costa, Sara Silva, Manuela Pintado · 2018 · Critical Reviews in Food Science and Nutrition
99. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
    Tuba M. Ansary, Daisuke Nakano, Akira Nishiyama · 2019 · International Journal of Molecular Sciences
100. An update on the safety of SGLT2 inhibitors
     André Jacques Scheen · 2019 · Expert Opinion on Drug Safety